SEARCH RESULTS

4945 RESULTS

In Phase 2, Donanemab Curbs Cognitive Decline in Early Alzheimer’s

RESEARCH NEWS 2021-01-12 Research News The Alzheimer’s field begins 2021 with a glimmer of good news: Donanemab, a monoclonal antibody that recognizes a pyroglutamated form of Aβ, slowed cognitive decline in people with early AD. That was the upshot of the topline results of the

Gilbert Gallardo


Washington University School of Medicine
St. Louis, United States

Current Filters

  • Date Range : Jan 2021 to Apr 2021 x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE